Title: Evaluation of clinical effects of a multidisciplinary-collaborated cancer support team
for gastrointestinal cancer chemotherapy: prospective observational study protocol of M-CAST
study
Version: 9 Date: 23 Apr 2023
Reviewer's report:
1. What exactly does "patients requiring intervention by the MCST" in the eligibility criteria
refer to? This statement appears to include all patients without stipulation.
2. The authors state the endpoint as "the number of patients improving side effects before and
after the intervention. What exactly does this improvement refer to, an improvement in CTC-
AE rates?
3. As noted in the discussion, even without MCST, most side effects can be improved by
reducing or discontinuing the drug; the role of MCST can only be assessed by drug dose
intensity. Please explain clearly the setting why you set the endpoints.
4. I think the authors should include within the INTRODUCTION the treatment completion rate
and side effects in the absence of MCST.
Title: Evaluation of clinical effects of a multidisciplinary-collaborated cancer support team
for gastrointestinal cancer chemotherapy: prospective observational study protocol of M-CAST
study
Version: 9 Date: 23 Apr 2023
Reviewer's report:
1. What exactly does "patients requiring intervention by the MCST" in the eligibility criteria
refer to? This statement appears to include all patients without stipulation.
2. The authors state the endpoint as "the number of patients improving side effects before and
after the intervention. What exactly does this improvement refer to, an improvement in CTC-
AE rates?
3. As noted in the discussion, even without MCST, most side effects can be improved by
reducing or discontinuing the drug; the role of MCST can only be assessed by drug dose
intensity. Please explain clearly the setting why you set the endpoints.
4. I think the authors should include within the INTRODUCTION the treatment completion rate
and side effects in the absence of MCST.
Please review this paper.
user
Title: Evaluation of clinical effects of a multidisciplinary-collaborated cancer support team
for gastrointestinal cancer chemotherapy: prospective observational study protocol of M-CAST
study
Version: 9 Date: 23 Apr 2023
Reviewer's report:
1. What exactly does "patients requiring intervention by the MCST" in the eligibility criteria
refer to? This statement appears to include all patients without stipulation.
2. The authors state the endpoint as "the number of patients improving side effects before and
after the intervention. What exactly does this improvement refer to, an improvement in CTC-
AE rates?
3. As noted in the discussion, even without MCST, most side effects can be improved by
reducing or discontinuing the drug; the role of MCST can only be assessed by drug dose
intensity. Please explain clearly the setting why you set the endpoints.
4. I think the authors should include within the INTRODUCTION the treatment completion rate
and side effects in the absence of MCST.
assistant